These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22215155)
1. Researchers still seek clinical benefit in raising levels of good cholesterol. Mitka M JAMA; 2012 Jan; 307(1):21-2. PubMed ID: 22215155 [No Abstract] [Full Text] [Related]
2. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. Pirillo A; Norata GD; Catapano AL Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430 [TBL] [Abstract][Full Text] [Related]
8. Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk. Perlmutter D; Golomb B; Sinatra S; Campbell AW Altern Ther Health Med; 2013; 19 Suppl 1():14-25. PubMed ID: 23981463 [No Abstract] [Full Text] [Related]
9. CETP inhibition shows promise as way to reduce cardiovascular disease risk. Mitka M JAMA; 2011 Jan; 305(2):136-7. PubMed ID: 21224449 [No Abstract] [Full Text] [Related]
10. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Nicholls SJ; Uno K; Kataoka Y Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787 [TBL] [Abstract][Full Text] [Related]
15. Controversies on HDL: should it be a target biomarker in patients with lipid disorders? Nicholls SJ; Andrews J; Duong M Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977 [TBL] [Abstract][Full Text] [Related]
16. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?]. Alexa ID; Panaghiu L; Ungureanu G Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166 [TBL] [Abstract][Full Text] [Related]
17. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
18. Should every patient with diabetes receive a statin? Dembowski E; Davidson MH Pol Arch Med Wewn; 2008; 118(7-8):398-401. PubMed ID: 18714733 [No Abstract] [Full Text] [Related]
19. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
20. [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?]. Einecke D MMW Fortschr Med; 2011 Dec; 153(49-50):17-8. PubMed ID: 22308584 [No Abstract] [Full Text] [Related] [Next] [New Search]